139 related articles for article (PubMed ID: 12956897)
1. Inducing a change in the pharmacokinetics and biodistribution of poly-L-lysine in rats by complexation with heparin.
Johnston TP; Kuchimanchi KR; Alur H; Chittchang M; Mitra AK
J Pharm Pharmacol; 2003 Aug; 55(8):1083-90. PubMed ID: 12956897
[TBL] [Abstract][Full Text] [Related]
2. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
[TBL] [Abstract][Full Text] [Related]
3. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
4. Carbamylation decreases the cytotoxicity but not the drug-carrier properties of polylysines.
Ekrami HM; Shen WC
J Drug Target; 1995; 2(6):469-75. PubMed ID: 7773608
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
6. Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.
Kaminskas LM; Boyd BJ; Karellas P; Henderson SA; Giannis MP; Krippner GY; Porter CJ
Mol Pharm; 2007; 4(6):949-61. PubMed ID: 17953445
[TBL] [Abstract][Full Text] [Related]
7. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.
Aliabadi HM; Brocks DR; Lavasanifar A
Biomaterials; 2005 Dec; 26(35):7251-9. PubMed ID: 16005061
[TBL] [Abstract][Full Text] [Related]
8. Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation.
Oie CI; Olsen R; Smedsrød B; Hansen JB
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G520-8. PubMed ID: 18063704
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.
Amantana A; Moulton HM; Cate ML; Reddy MT; Whitehead T; Hassinger JN; Youngblood DS; Iversen PL
Bioconjug Chem; 2007; 18(4):1325-31. PubMed ID: 17583927
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs.
Zhang C; Qu G; Sun Y; Yang T; Yao Z; Shen W; Shen Z; Ding Q; Zhou H; Ping Q
Eur J Pharm Sci; 2008 Apr; 33(4-5):415-23. PubMed ID: 18337069
[TBL] [Abstract][Full Text] [Related]
11. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
12. An adduct of cis-diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: synthesis and cytotoxic properties.
Bogdanov AA; Martin C; Bogdanova AV; Brady TJ; Weissleder R
Bioconjug Chem; 1996; 7(1):144-9. PubMed ID: 8742003
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and organ distribution of liposome-encapsulated L-carnitine in rats.
Jäger W; Koch HP
Arzneimittelforschung; 1993 Sep; 43(9):974-7. PubMed ID: 8240461
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity].
Jacobs C; Grebe S; Kietzmann M; Mischke R
Dtsch Tierarztl Wochenschr; 1999 Nov; 106(11):478-81. PubMed ID: 10609418
[TBL] [Abstract][Full Text] [Related]
16. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance.
Palm M; Mattsson C
Thromb Haemost; 1987 Oct; 58(3):932-5. PubMed ID: 2829379
[TBL] [Abstract][Full Text] [Related]
18. Indium-111 DTPA-heparin: radiolabeling, pharmacokinetics, and biodistribution following intravenous administration in rat and rabbit.
Bunting RW; Wilkinson RA; Callahan RJ; Strauss HW; Fischman AJ
Thromb Res; 1998 Jan; 89(1):23-30. PubMed ID: 9610757
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.
Townsend RW; Zutshi A; Bekersky I
Drug Metab Dispos; 2001 May; 29(5):681-5. PubMed ID: 11302934
[TBL] [Abstract][Full Text] [Related]
20. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
